Stocks Health care DMAC

NASDAQ · Health care

DiaMedica Therapeutics Inc. (DMAC)

It posted a net loss of $37.5M. In fiscal 2025 capital spending exceeded operating cash flow by $29.1M. At June 30, 2026 it held $5.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.

Watch DMAC in 60 seconds

Follow DMAC

Free, no password. An email when DMAC files with the SEC.

Key facts about DiaMedica Therapeutics Inc.

Net worth

DiaMedica Therapeutics Inc. has a market value (market cap) of $521.5M at the latest share price, and shareholders' equity of $38.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Revenue and profit

In fiscal 2018 revenue was $500K, with a net loss of $5.7M.

Cash flow

In fiscal 2025 operations used $29.1M of cash.

Latest report

The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 10, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR

Next earnings report

DiaMedica Therapeutics Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.

What DiaMedica Therapeutics Inc. does

DiaMedica Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker DMAC.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What DiaMedica Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. August 11, 2026
   Employee stock plan registration S-8
2. August 10, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.19 versus -$0.18.
3. August 10, 2026
   Quarterly results 8-K
4. May 21, 2026
   Shareholder vote results 8-K
5. May 6, 2026
   Quarterly report 10-Q · period to March 31, 2026Diluted EPS -$0.19 versus -$0.18.
6. May 6, 2026
   Quarterly results 8-K
7. April 1, 2026
   Annual report to shareholders ARS
8. April 1, 2026
   Additional proxy material DEFA14A
9. April 1, 2026
   Proxy statement DEF 14A
10. March 31, 2026
    Quarterly results 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 12, 2026. Insider transactions on SEC

Insider trades

What the people running DiaMedica Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns DMAC

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: John Fichthorn 0.3% (February 17, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

5 insiders reported holding 9,499,032 shares in total, about $91.9M at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about DMAC

What does DiaMedica Therapeutics Inc. do?

DiaMedica Therapeutics Inc. is a company in the Health care sector, listed on NASDAQ as DMAC. Its shares trade on NASDAQ under the ticker DMAC.

What is DiaMedica Therapeutics Inc.'s net worth?

DiaMedica Therapeutics Inc. has a market value (market cap) of $521.5M at the latest share price, and shareholders' equity of $38.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is DiaMedica Therapeutics Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $37.5M.

When did DiaMedica Therapeutics Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from August 12, 2026.

When is DiaMedica Therapeutics Inc.'s next earnings report?

DiaMedica Therapeutics Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.

Similar companies

Compare DMAC with

Compare DMAC with any company

Follow DMAC

Get an email when DiaMedica Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow DMAC

Free, no password. An email when DMAC files with the SEC.

Where the numbers come from

Financial figures are the values DiaMedica Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.